- Home
- SBFM vs KPRX Comparison
SBFM vs KPRX Comparison
Compare SBFM & KPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SBFM
- KPRX
- Stock Information
- Founded
- SBFM 2006
- KPRX 1998
- Country
- SBFM United States
- KPRX United States
- Employees
- SBFM N/A
- KPRX N/A
- Industry
- SBFM Biotechnology: Pharmaceutical Preparations
- KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- SBFM Health Care
- KPRX Health Care
- Exchange
- SBFM Nasdaq
- KPRX Nasdaq
- Market Cap
- SBFM 7.7M
- KPRX 9.1M
- IPO Year
- SBFM N/A
- KPRX N/A
- Fundamental
- Price
- SBFM $1.54
- KPRX $2.85
- Analyst Decision
- SBFM Strong Buy
- KPRX Strong Buy
- Analyst Count
- SBFM 1
- KPRX 1
- Target Price
- SBFM $15.00
- KPRX $10.00
- AVG Volume (30 Days)
- SBFM 183.7K
- KPRX 86.4K
- Earning Date
- SBFM 08-15-2025
- KPRX 08-08-2025
- Dividend Yield
- SBFM N/A
- KPRX N/A
- EPS Growth
- SBFM N/A
- KPRX N/A
- EPS
- SBFM N/A
- KPRX N/A
- Revenue
- SBFM $36,234,578.00
- KPRX $20,000.00
- Revenue This Year
- SBFM $192.48
- KPRX N/A
- Revenue Next Year
- SBFM N/A
- KPRX N/A
- P/E Ratio
- SBFM N/A
- KPRX N/A
- Revenue Growth
- SBFM 35.51
- KPRX N/A
- 52 Week Low
- SBFM $1.17
- KPRX $2.51
- 52 Week High
- SBFM $7.60
- KPRX $4.86
- Technical
- Relative Strength Index (RSI)
- SBFM 57.58
- KPRX 40.98
- Support Level
- SBFM $1.42
- KPRX $2.68
- Resistance Level
- SBFM $1.75
- KPRX $2.94
- Average True Range (ATR)
- SBFM 0.12
- KPRX 0.16
- MACD
- SBFM 0.01
- KPRX -0.03
- Stochastic Oscillator
- SBFM 61.81
- KPRX 23.99
About SBFM Sunshine Biopharma Inc.
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. Through its subsidiaries, the company has various generic prescription drugs on the market in Canada and is also involved in developing and selling OTC supplements. In addition, the company is conducting a proprietary drug development program, which is comprised of K1.1 mRNA targeted for liver cancer and SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections.
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.